ACCA SBR — Strategic Business Reporting Practice Exam 6

SECTION A - QUESTION 1

AeroBreeze Group (AB) is a multinational entity operating in the renewable energy sector, specifically offshore wind farms. AB prepares its consolidated financial statements in accordance with IFRS Accounting Standards to 31 December 20X5. The functional and presentation currency is the Dollar ($).

Event 1: Step Acquisition of Solaris
On 1 January 20X3, AB acquired a 15% equity interest in Solaris, a foreign entity operating in the solar panel manufacturing sector, for $10 million. AB made an irrevocable election to measure this investment at fair value through other comprehensive income (FVOCI). The functional currency of Solaris is the Dinar (D).

On 1 July 20X5, AB acquired a further 45% of the equity shares in Solaris for $40 million, gaining control. On this date, the fair value of the original 15% equity interest was $14 million. The fair value of the non-controlling interest (NCI), measured at full fair value, was $35 million. The identifiable net assets of Solaris at 1 July 20X5 had a fair value of $70 million.

Event 2: Contingent Consideration
As part of the 1 July 20X5 acquisition agreement, AB agreed to pay the former owners of Solaris an additional $5 million on 31 December 20X6 if Solaris achieves a cumulative megawatt production target. At the acquisition date, the fair value of this contingent consideration was estimated at $3 million. By 31 December 20X5, due to exceptional production rates, the fair value of the contingent consideration was reassessed at $4.5 million.

Event 3: Sale and Leaseback
On 1 October 20X5, AB sold a specialized offshore wind turbine to a financial institution for its fair value of $20 million. The carrying amount of the turbine prior to the sale was $15 million. Immediately following the sale, AB leased the turbine back for 5 years, which represents the remaining useful economic life of the asset. The present value of the annual lease payments, discounted at AB's incremental borrowing rate, is $12 million. The transfer of the turbine satisfies the requirements of IFRS 15 Revenue from Contracts with Customers to be accounted for as a sale.

Required:
(a) Explain, with supporting calculations, how the step acquisition of Solaris should be accounted for in the consolidated financial statements of AB for the year ended 31 December 20X5. Your answer should address the treatment of the previously held interest, the calculation of goodwill, and the implications of Solaris having a different functional currency (IAS 21). (15 marks)

(b) Discuss the correct accounting treatment for the contingent consideration at the acquisition date (1 July 20X5) and at the reporting date (31 December 20X5). (7 marks)

(c) Advise AB on the accounting treatment for the sale and leaseback transaction of the wind turbine for the year ended 31 December 20X5, including relevant calculations. (8 marks)

SECTION A - QUESTION 2

GenoCure is a biotechnology company developing advanced gene therapies. The company is preparing its financial statements for the year ended 31 October 20X5. GenoCure is currently seeking a lucrative Initial Public Offering (IPO) in early 20X6.

You are the newly appointed Chief Financial Officer (CFO), a qualified accountant. The Chief Executive Officer (CEO), who is also the majority shareholder, has presented you with two issues:

Issue 1: Research and Development (R&D)
During the year, GenoCure spent $12 million on a new gene therapy project, 'Helix-X'. $4 million was spent on early-stage laboratory research. The remaining $8 million was spent on Phase 1 clinical trials. While the Phase 1 trials showed promising safety profiles, efficacy has not yet been proven, and regulatory approval is at least three years away. The CEO has instructed you to capitalize the entire $12 million as an intangible asset, stating, "Our investors need to see a strong balance sheet for the IPO. If we expense this, our profit margins will look terrible, and the IPO valuation will collapse."

Issue 2: Related Party Transaction
GenoCure outsourced its data analysis for the clinical trials to 'DataGen', a company wholly owned by the CEO's brother. GenoCure paid DataGen $3 million for these services. Independent market analysis indicates that the arm's length commercial rate for identical services is $1.5 million. The CEO has told you not to disclose this transaction in the financial statements, arguing, "It's a standard service contract, and disclosing it will just invite unnecessary scrutiny from potential IPO investors."

Required:
(a) Discuss the correct accounting treatment for the R&D expenditure under IAS 38 Intangible Assets, and the transaction with DataGen under IAS 24 Related Party Disclosures. (10 marks)

(b) Discuss the ethical and professional issues you face as the CFO of GenoCure, and recommend appropriate actions you should take to resolve them. (10 marks)

SECTION B - QUESTION 3

AgriYield is a pioneering agri-tech company that operates large-scale, climate-controlled vertical farms. The company prepares its financial statements to 31 March 20X6.

Event 1: Biological Assets
AgriYield has developed a proprietary, genetically modified strain of strawberries designed specifically for vertical farming. At 31 March 20X6, AgriYield holds a significant inventory of these growing strawberry plants. Because this strain is proprietary, there is no active market for these specific plants. The finance director has proposed valuing the growing plants at historical cost (seeds, labor, and nutrients), arguing that fair value cannot be measured reliably under IAS 41 Agriculture.

Event 2: Government Grant
On 1 April 20X5, AgriYield received a $10 million government grant. The grant was provided to assist with the purchase of specialized LED lighting systems for a new vertical farm in an economically deprived area. The conditions of the grant stipulate that AgriYield must operate the farm and employ at least 50 local workers for a period of five years. If these conditions are not met, the grant is repayable in full. The LED lighting systems cost $25 million, have a useful life of 10 years, and were purchased and brought into use on 1 April 20X5. AgriYield intends to meet all grant conditions.

Event 3: Climate Risk and Stakeholder Reporting
AgriYield's institutional investors are increasingly focused on Environmental, Social, and Governance (ESG) metrics. They have requested detailed information on how climate change impacts the company's financial statements. AgriYield's traditional outdoor farming competitors are suffering from severe droughts, which has increased the market price of strawberries, benefiting AgriYield. However, AgriYield's vertical farms consume massive amounts of electricity, and impending carbon taxes (transition risks) could severely impact future cash flows.

Required:
(a) Advise AgriYield on the correct accounting treatment for the biological assets (growing strawberry plants) under IAS 41 and IFRS 13, and the government grant under IAS 20 for the year ended 31 March 20X6. (12 marks)

(b) Discuss how the physical and transition risks of climate change should be reflected in AgriYield's financial statements (with specific reference to IAS 36 Impairment of Assets and IAS 37 Provisions, Contingent Liabilities and Contingent Assets). Furthermore, explain the importance of sustainability reporting to AgriYield's investors. (13 marks)

SECTION B - QUESTION 4

BlockPay is a rapidly growing financial technology (FinTech) company that operates a cryptocurrency exchange and a digital payment gateway. The company prepares its financial statements to 31 December 20X5.

Event 1: Cryptocurrency Holdings
BlockPay holds two types of cryptocurrency assets:

1. 'Own Account': BlockPay holds $15 million in Bitcoin for its own investment purposes, intending to benefit from long-term capital appreciation. There is an active market for Bitcoin.
2. 'Client Account': BlockPay holds $50 million in various cryptocurrencies on behalf of its customers in digital wallets. The customers retain the right to withdraw these assets at any time. BlockPay's terms of service state that it does not have legal ownership of these client assets, but BlockPay holds the cryptographic 'private keys' required to access and transfer them.

Event 2: Revenue Recognition
BlockPay allows users to buy and sell cryptocurrencies on its platform. BlockPay charges a 2% transaction fee on the value of every trade executed. BlockPay does not purchase the cryptocurrency before transferring it to the buyer; it merely matches buyers and sellers using its proprietary algorithm. During the year, the total value of trades executed on the platform was $1 billion. The finance director wants to recognize $1 billion as revenue and $980 million as cost of sales to inflate the company's top-line revenue figure.

Event 3: Regulatory Investigation
In November 20X5, the financial regulator launched an investigation into BlockPay for alleged breaches of Anti-Money Laundering (AML) regulations occurring earlier in the year. BlockPay's legal counsel advises that it is probable (a 75% likelihood) that BlockPay will be found liable. The lawyers estimate the fine will be between $2 million and $6 million, with any amount in that range being equally likely. The investigation has attracted significant media attention, and BlockPay's primary lenders have requested a meeting to discuss the implications.

Required:
(a) Discuss the correct accounting treatment for the cryptocurrencies held on BlockPay's 'Own Account' and 'Client Account'. (9 marks)

(b) Advise BlockPay on the correct revenue recognition for the transaction fees under IFRS 15 Revenue from Contracts with Customers, specifically addressing the finance director's proposal. (8 marks)

(c) Explain how the regulatory investigation should be treated in the financial statements under IAS 37 Provisions, Contingent Liabilities and Contingent Assets, and discuss the potential impact of this disclosure on BlockPay's lenders and regulators (stakeholders). (8 marks)